Method and Composition for the Treatment of Cardiac Hypertrophy
AssigneeBoard of Regents, The University of Texas System
InventorsHarold R. Garner, Mounir Errami
Life of this patent
Estimating the term…
Abstract
The present invention includes compositions and methods treat a patient suffering from one or more symptoms of cardiac hypertrophy, hypertension and/or ischemia by administering a pharmaceutically effective amount of a pharmaceutical composition having an anti-epileptic drug and an antibiotic to the patient, for example, the anti-epileptic drug may be carbamazepine and the antibiotic may be doxycycline.
Claims20
A pharmaceutical composition to ameliorate one or more symptoms of myocardial infarction comprising carbamazepine and doxycycline.
A pharmaceutical composition to ameliorate one or more symptoms of myocardial infarction comprising a pharmaceutically effective amount of one or more compounds selected from doxycycline, metastat, MM1270(b), marimastat, BAY 12-9566, batimistat, prinomastat, somatostatin, masoprocol, isophlurophate, ovide, guanidine hydrochloride, calderol, tretinoin, thorazine, apomorphine, magnesium sulfate, stilbetin, buprenex, mixtures and combinations thereof.
A pharmaceutical composition to ameliorate one or more symptoms of myocardial infarction comprising an anti-epileptic drug.
A pharmaceutical composition to ameliorate one or more symptoms of myocardial infarction comprising an anti-epileptic drug and matrix metalloproteinase inhibitor.
A method of treating patient suffering hypertension, cardiac hypertrophy, myocardial infarction and/or ischemia comprising the steps of:
- administering a pharmaceutically effective amount of an anti-epileptic drug and a pharmaceutically effective amount of an matrix metalloproteinase inhibitor to a patient suffering one or more symptoms of hypertension, cardiac hypertrophy, myocardial infarction and/or ischemia.
A method of treating a patient suffering from myocardial infarction and/or cardiac hypertrophy by modulating the response of one or more cardiac hypertrophy-specific genes comprising the steps of:
- administering to the patient thought to be suffering from cardiac hypertrophy a pharmaceutically effective amount of an anti-epileptic drug or a pharmaceutically acceptable salt thereof and a pharmaceutically effective amount of an matrix metalloproteinase inhibitor or a pharmaceutically acceptable salt thereof, wherein one or more cardiac hypertrophy-specific genes are altered in response to treatment with doxycycline and carbamazepine.
A method for attenuating one or more complications of hypertension comprising the steps of:
- administering a pharmaceutically effective amount of a first compound to affect a β-adrenergic pathway;
- and
- administering a pharmaceutically effective amount of a second compound to affect a α-adrenergic pathway.
Dependencies are inferred from the claim text.